MedTrace Logo

PRECISE, a Study to Gather More Information About Bone Fractures and Survival in Castration-resistant PRostate Cancer (CRPC) patiEnts Treated With Radium-223 in Routine Clinical practIce in SwedEn

NCT04256993 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1434

Last updated 2024-01-16

No results posted yet for this study

Summary

In this observational study researchers want to gather more information about bone fractures and survival in castration-resistant prostate cancer (CRPC) patients treated with radium-223 in routine clinical practice in Sweden. The goal is to estimate the proportion of new cases (incidence) of symptomatic bone fractures and to estimate the proportion of death occurred in years of observation time per person (person years). Radium-223 (Ra-223) is an alpha particle-emitting radioactive agent approved for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC).

Conditions

Interventions

DRUG

Radium-223 dichloride (Xofigo, BAY88-8223)

Follow the physician's prescription in routine clinical practice. This study does not involve prescription of the drugs.

DRUG

Other standard care

Docetaxel, cabazitaxel, enzalutamide, abiraterone and others standard of care following the physician's prescription in routine clinical practice.

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-15
Primary Completion
2021-06-01
Completion
2021-06-01

Countries

  • Sweden

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04256993 on ClinicalTrials.gov